Claims
- 1. A method for treating infection by HIV comprising administering to a patient, in need of such treatment, a capsule or a compressed tablet pharmaceutical dosage form comprising a therapeutically effective amount of efavirenz and greater than about 10% by weight of a disintegrant relative to the total dry weight of the pharmaceutical dosage form.
- 2. A method for treating infection by HIV according to claim 1, wherein at least one disintegrant is selected from the group consisting of modified starches, croscarmellose sodium, carboxymethylcellulose calcium and crospovidone.
- 3. A method for treating infection by HIV according to claim 2, wherein the disintegrant is selected from one or more modified starches.
- 4. A method for treating infection by HIV according to claim 3, wherein the modified starch is sodium starch glycolate.
- 5. A method for treating infection by HIV according to claim 3 wherein the capsule or compressed tablet pharmaceutical dosage form is prepared using a wet granulation step containing efavirenz and one or more modified starches, wherein the modified starch is present in the wet granulation step in an amount of from about 10% to about 75% by weight relative to the total dry weight of the components of the wet granulation step.
- 6. A method for treating infection by HIV according to claim 3 wherein the modified starch is present in the wet granulation step of the manufacturing process in an amount of from about 20% to about 55% by weight relative to total dry weight of the components of the wet granulation step.
- 7. A method for treating infection by HIV according to claim 1 wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from about 5 to about 1000 mg.
- 8. A method for treating infection by HIV according to claim 1 wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from about 5 to about 500 mg.
- 9. A method for treating infection by HIV according to claim 1 wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from 500 to about 1000 mg.
- 10. A method for treating infection by HIV according to claim 1 wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from about 25 to about 350 mg.
- 11. A method for treating infection by HIV according to claim 1 wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from about 50 to about 200 mg.
- 12. A method for treating infection by HIV according to claim 5 or 6, wherein the wet granulation step is carried out in the presence of sodium lauryl sulfate.
- 13. A method for treating infection by HIV according to claim 12, wherein the sodium lauryl sulfate is present in an amount of about 0.1% to about 5% by weight relative to total dry weight of the components of the wet granulation step.
- 14. A method for treating infection by HIV according to claim 1, wherein the efavirenz is present in the pharmaceutical dosage form in an amount of from about 5 to about 800 mg.
- 15. A method for treating infection by HIV comprising administering to a patient, in need of such treatment, a pharmaceutical dosage form comprising:(a) a therapeutically effective amount of efavirenz; (b) a surfactant; (c) a disintegrant; (d) a binder; (e) a diluent; (f) a glidant; and (g) optionally additional pharmaceutically acceptable excipients; wherein at least one disintegrant is selected from the group consisting of modified starches, croscarmellose sodium, carboxymethylcellulose calcium and crospovidone and such disintegrant is present in an amount greater than about 10% by weight of the total dry weight of the capsule contents or the compressed tablet.
Parent Case Info
This application is a continuation of U.S. patent application Ser. No. 09/286,902, filed Apr. 6, 1999, which is now U.S. Pat. No. 6,238,695, and claims benefit of U.S. provisional application No. 60/080,925, filed Apr. 7, 1998.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5519021 |
Young et al. |
May 1996 |
A |
6238695 |
Makooi-Morehead et al. |
May 2001 |
B1 |
Foreign Referenced Citations (8)
Number |
Date |
Country |
0301006 |
Feb 1987 |
EP |
0394553 |
Oct 1990 |
EP |
207950 |
Aug 1991 |
HU |
WO 9520389 |
Aug 1994 |
WO |
WO 9622955 |
Aug 1996 |
WO |
WO 9641634 |
Dec 1996 |
WO |
WO 8705804 |
Oct 1997 |
WO |
WO 9961026 |
Dec 1999 |
WO |
Non-Patent Literature Citations (4)
Entry |
John E. Botzolakis and Larry L. Augsburger, 1988, Disintegrating Agents in Hard Gelatin Capsules, Drug Development and Industrial Pharmacy, 14(1), 29-41. |
Bolhuis et al., 1997, European Journal of Pharmaceutical Science, 5(2), 63-69. |
Te Wiernik, et al., 1992, ACTA Pharm Nord, 4(4), 239-44. |
Remington's Pharmaceutical Sciences 19th. Edition, p. 1619 (1995). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/080925 |
Apr 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/286902 |
Apr 1999 |
US |
Child |
09/824071 |
|
US |